In the May 2016 issue of Diagnostic and Interventional Cardiology the discussion centered around what the impediments to increasing the percentage of radial access procedures were and what the benefits are.

First the benefits

The article quotes Dr. Sunil Rao…

“In a cost-conscious environment, institutions are looking for ways to create value,” Rao explained. “Remember, value is healthcare outcomes per dollar spent, and I think in that equation, radial access is very attractive and we are seeing a lot more impetus to adopt radial right now.”

Radial access is only about 27% in the US. However, in Europe that share is upwards toward 80%. Why?

The impediments identified in the article are lack of training and institutional support. With the Angioexpand, we believe both of those impediments can be addressed. The Angioexpand can be used in femoral, radial or jugular access procedures. The simplicity of the system should convince even the most single-minded clinician that there is a better way.

Once the institution sees that they can reduce the number of microintroducers they inventory by half or more, the support will follow.

The Angioexpand is a patented, 510(k) cleared microintroducer that is available for license or other arrangements. Contact [email protected] or 877-522-4982 for more information.